Single domain antibodies directed against ebola virus
AssigneeSingh Biotechnology, LLC
InventorSunanda Singh
Life of this patent
Estimating the term…
Abstract
This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against targets that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
Claims16
An anti-Ebola VP24 single domain antibody (sdAb).
An anti-Ebola VP24 sdAb, wherein the anti-Ebola VP24 sdAb comprises the amino acid sequence as set forth in SEQ ID NO:
- 55.
A method of measuring the levels of an anti-Ebola VP24 sdAb in a sample from a subject, the method comprising the steps of:
- a) generating a mouse monoclonal antibody directed against one or more domains of a polypeptide comprising the amino acid sequence as set forth in SEQ ID NO:55;
- b) obtaining a sample from the subject;
- c) performing a quantitative immunoassay with the mouse monoclonal antibody and the sample to determine the amount of sdAb in a subject;
- and
- d) quantifying the amount of sdAb in the subject.
Dependencies are inferred from the claim text.